AstraZeneca’s Brilinta topples Bristol-Myers Squibb and Sanofi-Aventis’ Plavix in a head-to-head trial – again. Previous trials showed similar results. Brilinta prevented more serious cardiovascular events and deaths than Plavix. Brilinta seems to have an equivalent safety profile.
This study was an analysis of over 8,400 of the sickest patients from the large PLATO trial – which looked at over 18,000 patients internationally.
AstraZeneca will be filing for U.S. approval for Brilinta soon and the company expects approval early next year. This is good news for AstraZeneca as it hopes to steal some of Plavix’s $9 billion in sales.
This study was an analysis of over 8,400 of the sickest patients from the large PLATO trial – which looked at over 18,000 patients internationally.
AstraZeneca will be filing for U.S. approval for Brilinta soon and the company expects approval early next year. This is good news for AstraZeneca as it hopes to steal some of Plavix’s $9 billion in sales.